P450 pharmacogenetics in indigenous North American populations

Lindsay M. Henderson, Katrina G. Claw, Erica L. Woodahl, Renee F. Robinson, Bert Boyer, Wylie Burke, Kenneth E. Thummel

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Indigenous North American populations, including American Indian and Alaska Native peoples in the United States, the First Nations, Métis and Inuit peoples in Canada and Amerindians in Mexico, are historically under-represented in biomedical research, including genomic research on drug disposition and response. Without adequate representation in pharmacogenetic studies establishing genotype-phenotype relationships, Indigenous populations may not benefit fully from new innovations in precision medicine testing to tailor and improve the safety and efficacy of drug treatment, resulting in health care disparities. The purpose of this review is to summarize and evaluate what is currently known about cytochrome P450 genetic variation in Indigenous populations in North America and to highlight the importance of including these groups in future pharmacogenetic studies for implementation of personalized drug therapy.

Original languageEnglish (US)
Article number9
JournalJournal of Personalized Medicine
Volume8
Issue number1
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Pharmacogenetics
Population Groups
Healthcare Disparities
Inuits
Precision Medicine
North American Indians
North America
Mexico
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Population
Canada
Biomedical Research
Genotype
Phenotype
Safety
Drug Therapy
Research
Pharmacogenomic Testing
Alaska Natives

Keywords

  • Alaska native
  • Allele frequency
  • American Indian
  • Cytochrome P450
  • Drug metabolism
  • First Nations
  • Inuit
  • Mexican Amerindians
  • Pharmacogenetics

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Henderson, L. M., Claw, K. G., Woodahl, E. L., Robinson, R. F., Boyer, B., Burke, W., & Thummel, K. E. (2018). P450 pharmacogenetics in indigenous North American populations. Journal of Personalized Medicine, 8(1), [9]. https://doi.org/10.3390/jpm8010009

P450 pharmacogenetics in indigenous North American populations. / Henderson, Lindsay M.; Claw, Katrina G.; Woodahl, Erica L.; Robinson, Renee F.; Boyer, Bert; Burke, Wylie; Thummel, Kenneth E.

In: Journal of Personalized Medicine, Vol. 8, No. 1, 9, 01.03.2018.

Research output: Contribution to journalReview article

Henderson, LM, Claw, KG, Woodahl, EL, Robinson, RF, Boyer, B, Burke, W & Thummel, KE 2018, 'P450 pharmacogenetics in indigenous North American populations', Journal of Personalized Medicine, vol. 8, no. 1, 9. https://doi.org/10.3390/jpm8010009
Henderson, Lindsay M. ; Claw, Katrina G. ; Woodahl, Erica L. ; Robinson, Renee F. ; Boyer, Bert ; Burke, Wylie ; Thummel, Kenneth E. / P450 pharmacogenetics in indigenous North American populations. In: Journal of Personalized Medicine. 2018 ; Vol. 8, No. 1.
@article{fabd886c40ee40e1a1f907bde15c79e8,
title = "P450 pharmacogenetics in indigenous North American populations",
abstract = "Indigenous North American populations, including American Indian and Alaska Native peoples in the United States, the First Nations, M{\'e}tis and Inuit peoples in Canada and Amerindians in Mexico, are historically under-represented in biomedical research, including genomic research on drug disposition and response. Without adequate representation in pharmacogenetic studies establishing genotype-phenotype relationships, Indigenous populations may not benefit fully from new innovations in precision medicine testing to tailor and improve the safety and efficacy of drug treatment, resulting in health care disparities. The purpose of this review is to summarize and evaluate what is currently known about cytochrome P450 genetic variation in Indigenous populations in North America and to highlight the importance of including these groups in future pharmacogenetic studies for implementation of personalized drug therapy.",
keywords = "Alaska native, Allele frequency, American Indian, Cytochrome P450, Drug metabolism, First Nations, Inuit, Mexican Amerindians, Pharmacogenetics",
author = "Henderson, {Lindsay M.} and Claw, {Katrina G.} and Woodahl, {Erica L.} and Robinson, {Renee F.} and Bert Boyer and Wylie Burke and Thummel, {Kenneth E.}",
year = "2018",
month = "3",
day = "1",
doi = "10.3390/jpm8010009",
language = "English (US)",
volume = "8",
journal = "Journal of Personalized Medicine",
issn = "2075-4426",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - P450 pharmacogenetics in indigenous North American populations

AU - Henderson, Lindsay M.

AU - Claw, Katrina G.

AU - Woodahl, Erica L.

AU - Robinson, Renee F.

AU - Boyer, Bert

AU - Burke, Wylie

AU - Thummel, Kenneth E.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Indigenous North American populations, including American Indian and Alaska Native peoples in the United States, the First Nations, Métis and Inuit peoples in Canada and Amerindians in Mexico, are historically under-represented in biomedical research, including genomic research on drug disposition and response. Without adequate representation in pharmacogenetic studies establishing genotype-phenotype relationships, Indigenous populations may not benefit fully from new innovations in precision medicine testing to tailor and improve the safety and efficacy of drug treatment, resulting in health care disparities. The purpose of this review is to summarize and evaluate what is currently known about cytochrome P450 genetic variation in Indigenous populations in North America and to highlight the importance of including these groups in future pharmacogenetic studies for implementation of personalized drug therapy.

AB - Indigenous North American populations, including American Indian and Alaska Native peoples in the United States, the First Nations, Métis and Inuit peoples in Canada and Amerindians in Mexico, are historically under-represented in biomedical research, including genomic research on drug disposition and response. Without adequate representation in pharmacogenetic studies establishing genotype-phenotype relationships, Indigenous populations may not benefit fully from new innovations in precision medicine testing to tailor and improve the safety and efficacy of drug treatment, resulting in health care disparities. The purpose of this review is to summarize and evaluate what is currently known about cytochrome P450 genetic variation in Indigenous populations in North America and to highlight the importance of including these groups in future pharmacogenetic studies for implementation of personalized drug therapy.

KW - Alaska native

KW - Allele frequency

KW - American Indian

KW - Cytochrome P450

KW - Drug metabolism

KW - First Nations

KW - Inuit

KW - Mexican Amerindians

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=85041014899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041014899&partnerID=8YFLogxK

U2 - 10.3390/jpm8010009

DO - 10.3390/jpm8010009

M3 - Review article

AN - SCOPUS:85041014899

VL - 8

JO - Journal of Personalized Medicine

JF - Journal of Personalized Medicine

SN - 2075-4426

IS - 1

M1 - 9

ER -